The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments

Clicks: 347
ID: 120268
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #9 of 85 articles by views in Annals of hematology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The International Prognostic Score (IPS) is the most commonly used risk stratification tool for patients with advanced Hodgkin lymphoma (HL). It incorporates seven clinical parameters independently associated with a poorer outcome: male sex, age, stage IV, hemoglobin level, white blood cell and lymp …
Reference Key
a2020annalsthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bari A;Marcheselli R;Sacchi S;Re A;Pagani C;Tucci A;Botto B;Vitolo U;Molinari AL;Puccini B;Pulsoni A;Santoro A;Tani M;Nassi L;Meli E;Pavone V;Bonfichi M;Evangelista A;Gioia D;Levis A;Zinzani P; ;;
Journal Annals of hematology
Year 2020
DOI
DOI not found
URL
https://www.pubmed.gov/31872362/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male middle aged Clinical Trial Multicenter Study survival rate neoplasm staging antineoplastic combined chemotherapy protocols / administration & dosage* disease-free survival doxorubicin / administration & dosage autografts stem cell transplantation* pmid:31872362 pmc6976582 doi:10.1007/s00277-019-03893-7 alessia bari raffaella marcheselli fondazione italiana linfomi (onlus) bleomycin / administration & dosage dacarbazine / administration & dosage hodgkin disease* / diagnostic imaging hodgkin disease* / mortality hodgkin disease* / therapy positron-emission tomography vinblastine / administration & dosage

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.